Zheng Haosheng, Long Guojie, Zheng Yuzhen, Yang Xingping, Cai Weijie, He Shiyun, Qin Xianyu, Liao Hongying
Department of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
Guangdong Research Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
Cancers (Basel). 2022 Oct 29;14(21):5344. doi: 10.3390/cancers14215344.
SLC2A1 plays a pivotal role in cancer glycometabolism. SLC2A1 has been proposed as a putative driver gene in various cancers. However, a pan-cancer analysis of SLC2A1 has not yet been performed. In this study, we explored the expression and prognosis of SLC2A1 in pan-cancer across multiple databases. We conducted genetic alteration, epigenetic, and functional enrichment analyses of SLC2A. We calculated the correlation between SLC2A1 and tumor microenvironment using the TCGA pan-cancer dataset. We observed high expression levels of SLC2A1 with poor prognosis in most cancers. The overall genetic alteration frequency of SLC2A1 was 1.8% in pan-cancer, and the SLC2A1 promoter was hypomethylation in several cancers. Most m6A-methylation-related genes positively correlated with the expression of SLC2A1 in 33 TCGA cancers. Moreover, SLC2A1 was mainly related to the functions including epithelial-mesenchymal transition, glycolysis, hypoxia, cell-cycle regulation, and DNA repair. Finally, SLC2A1 positively associated with neutrophils and cancer-associated fibroblasts in the tumor microenvironment of most cancers and significantly correlated with TMB and MSI in various cancers. Notably, SLC2A1 was remarkably positively correlated with PD-L1 and CTLA4 in most cancers. SLC2A1 might serve as an attractive pan-cancer biomarker for providing new insights into cancer therapeutics.
溶质载体家族2成员1（SLC2A1）在癌症糖代谢中起关键作用。SLC2A1已被提出作为多种癌症中的一个假定驱动基因。然而，尚未对SLC2A1进行泛癌分析。在本研究中，我们在多个数据库中探索了SLC2A1在泛癌中的表达和预后情况。我们对SLC2A进行了基因改变、表观遗传和功能富集分析。我们使用TCGA泛癌数据集计算了SLC2A1与肿瘤微环境之间的相关性。我们观察到在大多数癌症中，SLC2A1表达水平高且预后不良。SLC2A1在泛癌中的总体基因改变频率为1.8%，并且在几种癌症中SLC2A1启动子呈低甲基化状态。在33种TCGA癌症中，大多数与N6-甲基腺苷（m6A）甲基化相关的基因与SLC2A1的表达呈正相关。此外，SLC2A1主要与上皮-间质转化、糖酵解、缺氧、细胞周期调控和DNA修复等功能相关。最后，在大多数癌症的肿瘤微环境中，SLC2A1与中性粒细胞和癌症相关成纤维细胞呈正相关，并且在各种癌症中与肿瘤突变负荷（TMB）和微卫星不稳定性（MSI）显著相关。值得注意的是，在大多数癌症中，SLC2A1与程序性死亡受体1配体（PD-L1）和细胞毒性T淋巴细胞相关蛋白4（CTLA4）显著正相关。SLC2A1可能作为一种有吸引力的泛癌生物标志物，为癌症治疗提供新的见解。
